| Not Yet Recruiting | IBM Dietary Surveillance Study NCT07535996 | Manchester Metropolitan University | — |
| Recruiting | Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease NCT07478172 | University of Missouri-Columbia | N/A |
| Not Yet Recruiting | Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications NCT07240649 | Jay C. Buckey Jr. | Phase 4 |
| Enrolling By Invitation | The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Followi NCT07072676 | LMU Klinikum | N/A |
| Recruiting | MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS) NCT07374107 | Myositis International Health & Research Collaborative Alliance Foundation | — |
| Enrolling By Invitation | Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disor NCT06605612 | LMU Klinikum | — |
| Active Not Recruiting | Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Ov NCT06153108 | University of Kansas Medical Center | — |
| Completed | The Risk of Falls Index for Patients With Neuromuscular Disorders NCT05890833 | LMU Klinikum | — |
| Completed | A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis NCT05721573 | Abcuro, Inc. | Phase 2 / Phase 3 |
| Unknown | Cell Therapy for IBM by Muscle Injection of ADSVF NCT05032131 | Assistance Publique - Hôpitaux de Paris | Phase 1 |
| Active Not Recruiting | Phase III Trial of Sirolimus in IBM NCT04789070 | University of Kansas Medical Center | Phase 3 |
| Unknown | Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease NCT05272969 | LMU Klinikum | — |
| Completed | Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells NCT04975841 | University of Kansas Medical Center | N/A |
| Active Not Recruiting | Sporadic Inclusion Body Myositis Natural History Study NCT05046821 | University of California, Irvine | — |
| Completed | A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With NCT04659031 | Abcuro, Inc. | Phase 1 |
| Completed | Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis NCT04421677 | University of Kansas Medical Center | Phase 1 |
| Terminated | Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial NCT04049097 | ZevraDenmark | Phase 3 |
| Completed | Establishing Muscle Impedance Parameters With Electrical Impedance Myography NCT03633318 | Yale University | — |
| Completed | Study of Pioglitazone in Sporadic Inclusion Body Myositis NCT03440034 | Johns Hopkins University | Phase 1 |
| Completed | Molecular Profile of the Evolution of Inclusion Body Myositis NCT03299335 | Centre Hospitalier Universitaire de Nice | N/A |
| Completed | Study of Arimoclomol in Inclusion Body Myositis (IBM) NCT02753530 | ZevraDenmark | Phase 2 |
| Completed | Environmental Risk Factors for Myositis in Military Personnel NCT01734369 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis NCT00898989 | Institut de Myologie, France | — |
| Completed | Arimoclomol in Sporadic Inclusion Body Myositis NCT00769860 | Richard Barohn, MD | Phase 2 / Phase 3 |
| Completed | Lithium in Inclusion Body Myositis (IBM) NCT00917956 | Phoenix Neurological Associates, LTD | — |
| Completed | Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body NCT00802815 | Washington University School of Medicine | EARLY_Phase 1 |
| Completed | Anakinra in Myositis NCT01165008 | Karolinska Institutet | Phase 2 / Phase 3 |
| Recruiting | Adult and Juvenile Myositis NCT00017914 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies NCT00001261 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |